Reviewing Insmed Incorporated (INSM)’s and ANI Pharmaceuticals Inc. (NASDAQ:ANIP)’s results

We are comparing Insmed Incorporated (NASDAQ:INSM) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Insmed Incorporated N/A 0.00 298.09M -3.88 0.00
ANI Pharmaceuticals Inc. 191.74M 3.48 N/A 1.18 46.66

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Insmed Incorporated 0.00% -81.8% -45.5%
ANI Pharmaceuticals Inc. 0.00% 0.2% 0.1%

Risk & Volatility

Insmed Incorporated’s 1.76 beta indicates that its volatility is 76.00% more volatile than that of Standard and Poor’s 500. ANI Pharmaceuticals Inc.’s 2.45 beta is the reason why it is 145.00% more volatile than Standard and Poor’s 500.

Liquidity

Insmed Incorporated has a Current Ratio of 10.1 and a Quick Ratio of 10.1. Competitively, ANI Pharmaceuticals Inc.’s Current Ratio is 3.3 and has 2.5 Quick Ratio. Insmed Incorporated’s better ability to pay short and long-term obligations than ANI Pharmaceuticals Inc.

Analyst Recommendations

In next table is given Insmed Incorporated and ANI Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Insmed Incorporated 0 1 4 2.80
ANI Pharmaceuticals Inc. 0 0 1 3.00

The upside potential is 22.04% for Insmed Incorporated with consensus target price of $30.4. Meanwhile, ANI Pharmaceuticals Inc.’s consensus target price is $70, while its potential upside is 24.36%. Based on the analysts view we can conclude, ANI Pharmaceuticals Inc. is looking more favorable than Insmed Incorporated.

Insider and Institutional Ownership

Insmed Incorporated and ANI Pharmaceuticals Inc. has shares held by institutional investors as follows: 0% and 84.7%. Insiders held 0.9% of Insmed Incorporated shares. Competitively, ANI Pharmaceuticals Inc. has 0.4% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Insmed Incorporated -10.5% -4.58% -21.07% -43.18% -42.91% -48.59%
ANI Pharmaceuticals Inc. -1.21% -0.63% -0.62% -17.28% -18.38% -14.79%

For the past year Insmed Incorporated was more bearish than ANI Pharmaceuticals Inc.

Summary

ANI Pharmaceuticals Inc. beats on 10 of the 11 factors Insmed Incorporated.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.